36552 Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 

in Phase I but who failed to fill their 

ARV prescriptions in the subsequent 30 

days of the Phase I consultation, and for 

participants who are >60 to <90 days 

late at the time the participant was 

determined to be study eligible. In 

Phase II, the Linkage Coordinator will 

lead a similar consultation as in Phase 

I, but will probe for more complex 

adherence barriers (e.g., mental health 

concerns) and referrals will be made 

accordingly. The participant will also be 

offered an evidence-informed mobile 

application (‘‘app’’) which is designed 

to support ART adherence and retention 

in care. 

The provider-level intervention will 

consist of a peer-to-peer clinician 

consultation delivered by clinicians 

from the Virginia Department of 

Health’s Advisory Committee to the 

Virginia Medication Assistance Program 

or by another HIV clinical expert. The 

peer-to-peer clinician consultations will 

involve introduction or reinforcement of 

HIV clinical guidelines for ART 

initiation, strategies to optimize ART 

adherence, and resources for supporting 

adherence for people with HIV. The 

consultation will be tailored to the 

needs of the provider participant. 

All analyses will be conducted at the 

patient level. Persons within the 

intervention arm will be followed 

prospectively for 12 months. At the end 

of the intervention arm follow-up 

period, persons within the usual care 

arm will be followed retrospectively for 

12 months. The primary study outcome 

of HIV viral suppression (HIV RNA 

<200 copies/mL) will be compared 

between study arms. 

CDC requests OMB approval to collect 

standardized information from 500 

AIMS study participants (460 

participants of the patient-level 

intervention and 40 participants of the 

provider-level intervention) and 500 

controls over the three-year project 

period. Secondary data will be 

abstracted from the Virginia Medicaid 

and Virginia Care Markers databases to 

determine study eligibility, to conduct 

the patient- and provider-level 

interventions, and to determine study 

outcomes. During the patient-level 

intervention, data will be collected on 

participants’ adherence barriers; this 

information will be used to refer 

participants to appropriate resources to 

assist their adherence to ART. During 

the provider-level intervention data will 

be collected to inform the peer-to-peer 

clinician consultation. 

CDC requests OMB approval for an 

estimated 687 burden hours annually. 

There are no costs to respondents other 

than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Participants ....................................... Verbal consent—participants ........... 460 1 15/60 115 

Provider participants ......................... Verbal consent—provider participants.40 1 15/60 10 

Participants ....................................... Verbal consent—control participants 

(for participants of provider-level 

intervention).

40 1 15/60 10 

Control participants ........................... Verbal consent—control participants 500 1 15/60 125 

PositiveLinks participants .................. PositiveLinks enrollment .................. 100 1 60/60 100 

Participants ....................................... Phase I interview .............................. 460 1 30/60 230 

Participants ....................................... Phase II interview ............................. 100 1 30/60 50 

Advisory Committee to the Virginia 

Medication Assistance Program 

member and other HIV clinical expects.

Clinician consultation ....................... 10 4 30/60 20 

Provider participants ......................... Clinician consultation ....................... 40 1 30/60 20 

Advisory Committee to the Virginia 

Medication Assistance Program 

member and other HIV clinical expects.

Post-consultation questionnaire ....... 10 4 10/60 7 

Total ........................................... ........................................................... ........................ ........................ ........................ 687 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–14752 Filed 7–9–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60 Day–21–0530; Docket No. CDC–2021– 

0064] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Energy Employees Occupational 

Illness Compensation Program Act 

(EEOICPA) Dose Reconstruction 

Interviews and Forms. This data 

collection permits claimants under 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 36553 

EEOICPA to provide information 

potentially useful in reconstructing 

radiation doses, and to confirm that they 

have no further information to submit. 

DATES: CDC must receive written 

comments on or before September 10, 

2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0064 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Energy Employees Occupational 

Illness Compensation Program Act 

(EEOICPA) Dose Reconstruction 

Interviews and Forms (OMB Control No. 

0920–0530, Exp. 1/31/2022)— 

Revision—National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

On October 30, 2000, the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000 (42 

U.S.C. 7384–7385) was enacted. This 

Act established a federal compensation 

program for employees of the 

Department of Energy (DOE) and certain 

of its contractors, subcontractors and 

vendors, who have suffered cancers and 

other designated illnesses as a result of 

exposures sustained in the production 

and testing of nuclear weapons. 

Executive Order 13179, issued on 

December 7, 2000, delegated authorities 

assigned to ‘‘the President’’ under the 

Act to the Departments of Labor, Health 

and Human Services, Energy and 

Justice. The Department of Health and 

Human Services (DHHS) was delegated 

the responsibility of establishing 

methods for estimating radiation doses 

received by eligible claimants with 

cancer applying for compensation. 

NIOSH is applying the following 

methods to estimate the radiation doses 

of individuals applying for 

compensation. 

In performance of its dose 

reconstruction responsibilities, under 

the Act, NIOSH is providing voluntary 

interview opportunities to claimants (or 

their survivors) individually, and 

providing them with the opportunity to 

assist NIOSH in documenting the work 

history of the employee by 

characterizing the actual work tasks 

performed. In addition, NIOSH and the 

claimant may identify incidents that 

may have resulted in undocumented 

radiation exposures, characterize 

radiological protection and monitoring 

practices, and identify co-workers and 

other witnesses, as may be necessary, to 

confirm undocumented information. In 

this process, NIOSH uses a computer 

assisted telephone interview (CATI) 

system, which allows interviews to be 

conducted more efficiently and quickly 

as opposed to a paper-based interview 

instrument. Both interviews are 

voluntary, and failure to participate in 

either or both interviews will not have 

a negative effect on the claim, although 

voluntary participation may assist the 

claimant by adding important 

information that may not be otherwise 

available. 

NIOSH uses the data collected in this 

process to complete an individual dose 

reconstruction that accounts, as fully as 

possible, for the radiation dose incurred 

by the employee in the line of duty for 

DOE nuclear weapons production 

programs. After dose reconstruction, 

NIOSH also performs a brief, voluntary 

final interview with the claimant to 

explain the results and to allow the 

claimant to confirm or question the 

records NIOSH has compiled. This will 

also be the final opportunity for the 

claimant to supplement the dose 

reconstruction record. 

At the conclusion of the dose 

reconstruction process, the claimant 

submits a form to confirm that the 

claimant has no further information to 

provide to NIOSH about the claim at 

this time. The form notifies the claimant 

that signing the form allows NIOSH to 

forward a dose reconstruction report to 

DOL and to the claimant, and closes the 

record on data used for the dose 

reconstruction. Signing this form does 

not indicate that the claimant agrees 

with the outcome of the dose 

reconstruction. The dose reconstruction 

results will be supplied to the claimant 

and to the DOL, the agency that will 

utilize them as one part of its 

determination of whether the claimant 

is eligible for compensation under the 

Act. 

CDC requests approval for an 

estimated 3,900 burden hours annually. 

There is no cost to respondents other 

than their time. 


khammond on DSKJM1Z7X2PROD with NOTICES
36554 Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondents Form name Number of respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Claimant ......................... Initial Interview ..................................................... 3,600 1 1 3,600 

Claimant ......................... Conclusion Form OCAS–1 .................................. 3,600 1 5/60 300 

Total ........................ .............................................................................. ........................ ........................ ........................ 3,900 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–14753 Filed 7–9–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Board on Radiation and 

Worker Health (ABRWH), National 

Institute for Occupational Safety and 

Health (NIOSH) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC, announces the following meeting 

of the Advisory Board on Radiation and 

Worker Health (ABRWH or the Advisory 

Board). This meeting is open to the 

public, limited only by the space 

available. The are 200 spaces for the 

audio conference and computer lines 

combined. The public is welcome to 

submit written comments in advance of 

the meeting, to the contact person 

below. Written comments received in 

advance of the meeting will be included 

in the official record of the meeting. The 

public is also welcomed to listen to the 

meeting by joining a teleconference line 

and/or computer connection 

(information below). 

DATES: The meeting will be held on 

August 18, 2021, from 1:00 p.m. to 6:30 

p.m., EDT, and August 19, 2021, from 

1:00 p.m. to 4:15 p.m., EDT. A public 

comment session will be held on August 

18, 2021 at 5:30 p.m. and will conclude 

at 6:30 p.m., EDT or following the final 

call for public comment, whichever 

comes first. Written comments must be 

received on or before August 11, 2021. 

ADDRESSES: You may submit comments 

by mail to: Sherri Diana, National 

Institute for Occupational Safety and 

Health, 1090 Tusculum Avenue, MS C– 

34, Cincinnati, Ohio 45226. Meeting 

Information: The USA toll-free dial-in 

numbers are: +1 669 254 5252 US (San 

Jose); +1 646 828 7666 US (New York); 

+1 551 285 1373 US; +1 669 216 1590 

US (San Jose); The Meeting ID is: 161 

786 4323 and the Passcode is: 76650371; 

Web conference by Zoom meeting 

connection: https://cdc.zoomgov.com/j/ 

1617864323?pwd=NWFzTmNlbU

tmOFFmMlNlbmZ0WUczZz09. 

FOR FURTHER INFORMATION CONTACT: 

Rashaun Roberts, Ph.D., Designated 

Federal Officer, NIOSH, CDC, 1090 

Tusculum Avenue, Mailstop C–24, 

Cincinnati, Ohio 45226; Telephone: 

(513) 533–6800; Toll Free: 1 (800) CDC– 

INFO; email: ocas@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Background: The Advisory Board was 

established under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000 to advise the 

President on a variety of policy and 

technical functions required to 

implement and effectively manage the 

new compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines 

which have been promulgated by the 

Department of Health and Human 

Services (HHS) as a final rule, advice on 

methods of dose reconstruction which 

have also been promulgated by HHS as 

a final rule, advice on the scientific 

validity and quality of dose estimation 

and reconstruction efforts being 

performed for purposes of the 

compensation program, and advice on 

petitions to add classes of workers to the 

Special Exposure Cohort (SEC). In 

December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, 

which subsequently delegated this 

authority to the CDC. NIOSH 

implements this responsibility for CDC. 

The Advisory Board’s charter was 

issued on August 3, 2001, renewed at 

appropriate intervals, rechartered on 

March 22, 2020, and will terminate on 

March 22, 2022. 

Purpose: This Advisory Board is 

charged with (a) providing advice to the 

Secretary, HHS, on the development of 

guidelines under Executive Order 

13179; (b) providing advice to the 

Secretary, HHS, on the scientific 

validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advising the Secretary 

on whether there is a class of employees 

at any Department of Energy facility 

who were exposed to radiation but for 

whom it is not feasible to estimate their 

radiation dose, and on whether there is 

reasonable likelihood that such 

radiation doses may have endangered 

the health of members of this class. 

Matters To Be Considered: The agenda 

will include discussions on the 

following: NIOSH Program Update; 

Department of Labor Program Update; 

Department of Energy Program Update; 

SEC Petitions Update; Procedures 

Review Finalization/Document 

Approvals; Oak Ridge National 

Laboratory (X–10), Y–12 SEC Petition 

#250 Addendum Update (Oak Ridge, 

Tennessee; 1987–1994), and a Board 

Work Session. Agenda items are subject 

to change as priorities dictate. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–14685 Filed 7–9–21; 8:45 am] 

BILLING CODE 4163–18–P 


khammond on DSKJM1Z7X2PROD with NOTICES